Bob, you, and good Thank morning, everyone.
of As incredibly Team accomplishments Akeso. and enthusiastic Summit remain I with partnership Bob the about our mentioned,
touching Before conducted highlights like clinical of the clinical ivonescimab, to ivonescimab. have speak would the expansive we development to on I with work
trials patients over with to been been clinical Between clinical X,XXX have treated date around evaluating Summit globe have the and Akeso, ivonescimab. XX ivonescimab worldwide. There in studies
candidate programs in and across are Phase non-small-cell currently settings III are lead for While lung clinical focused tumor solid evaluating non-small Summit beyond the cancer. of in lung X our cancer, our ivonescimab Akeso trials cell
X we are both of which sponsoring course, HARMONi-X. clinical Phase HARMONi and trials, Of III are studies:
validated in highly these ivonescimab targeting VEGF. both one into only antibody a is of our PD-X and As X simultaneously together licensed reminder, VEGF brings in the territories. mechanism III PD-X molecule action bispecific novel Phase Ivonescimab
of to some our like on recent catalysts remainder Next, the upcoming would achievements as well I this touch for year. review as
of We to At Akeso became was XXXX. or immediately first of Phase half Akeso ivonescimab several at conferences. quarter helped and reminder, X our effective partnership of our a As completing got clinical was featured at began fourth in medical the work in enrollment XXXX beginning the the enrolling in to the first HARMONi-X in enrollment time, ensure and with XXXX, enrolled patient HARMONi III trials.
its was pivotal ASCO around and catalyst X a with the XXXX of quarter occurring for moment second major conference. time events The ivonescimab of the XXXX development
the progressed non-small III patients trial published Phase featured following in EGFR-TKI. Journal advanced subsequently ASCO HARMONi-A Akeso supported in an oral an the by Medical and was of HARMONi-A This for data who marketing or approval American clinical JAMA. Association with received presentation study at Ivonescimab cancer lung in China was cell
tumors presented a positive PD-LX major and as that for HARMONi-X met tumors progression-free including Improvements forward in first-line observed were significant monotherapy non-squamous well medical high monotherapy prespecified announced was head-to-head statistical clinically data can additional ivonescimab squamous histologies. survival benefit conference analysis in this non-small against in as achieved of a which broadly to a meaningful subgroups, in also in We lung whose with and pembrolizumab at its endpoint trial primary patients PD-LX We cancer and in PFS expression. China patients interim low expressing HARMONi-X PD-LX look across having quarter.
Looking to the remainder of XXXX.
the this and In readout, multiregional II expect complete HARMONi-X Phase to data lung and plan head World multiple colorectal lung additional breast titles year cancer addition in data medical on the to and neck in studies and ESMO ivonescimab in in our at featuring indications trial in months, including released cancer triple-negative Conference recently we later conferences ESMO. abstract and to non-lung cancer. presented HARMONi cancer, coming the Phase be II enrollment
and Akeso our from strong such multiple to ongoing solid studies informing late-stage We in supporting partnership Summit's with licensed strategy collaboration created our have development we data own clinical as territories. in a leverage are tumor fortunate
study cancer advanced take lung metastatic Akeso disease review and highlight for to ivonescimab patients study EGFR-TKI metastases. earnings for EGFR-mutant in wanted sites after double-blinded both patients Starting non-small plus call exposure opportunity cell region the meaningful This updates patients across HARMONi-A. of with treatment evaluating and chemotherapy and placebo-controlled this and presence is XX occurring a versus this some design were to or third-generation from With placebo results. on III Phase treatment. EGFR-TKI China HARMONi-X past III XXX Phase plus the and enrolled trial HARMONi-A chemotherapy quarter's quarter, progression with to brain stratified were single key we randomized
are own study XX% met of per trial. reduction intended a approximately death progression who committee progression-free ratio analysis, be patients received the the representing chemotherapy. primary EGFR-TKI XX% entering third-generation radiologic of to of HARMONi-A of HARMONi-A, a risk the independent in a prior in included compared PFS review As disease to HARMONi-A, In our HARMONi endpoint reminder, X.XX, hazard in survival those was a representing patients to achieving or
of hazard osimertinib experienced or X.XX is EGFR-TKI a to expected death subgroup of or in like this trial half receiving reduced disease complete of ratio progression of third-generation second XX% the the risk Additionally, of a enrollment as patients our HARMONi year.
for We remain strongly by ivonescimab. the encouraged opportunity
X an its X.X% manageable adverse review median overall was a in arm the tolerated with X.X% of safety ratio Overall and for in analysis events addition, Treatment-related marketing ivonescimab XX% to requested a treatment China. discontinuation approval of data the leading were there reported X.XX. maturity a Survival HARMONi-A At Chinese of profile. In adverse in in placebo in in VEGF-related either Authority There the no compared survival arm. Regulatory trend positive patients events X.X% hazard arm reported ivonescimab the by survival a Ivonescimab to immune-related observed X.X% placebo no placebo adverse data well in of bleeding or in or were in reported higher and arm, were X.X% in the potential the of arm. patients arm. Grade patients of grade either in arm Grade patients events higher or of the deaths were were versus treatment treatment arm. in versus X.X% arm higher X the was part showed of as demonstrated X the events
HARMONi-X, or disease. by to demonstrated progression-free Radiologic non-squamous have results over study of in cell statistically monotherapy than XX% TPS to improvement Patients ivonescimab this against high-level significant, meaningful ivonescimab TPS metastatic region PD-LX locally Akeso stage survival histology as multicenter primary III by whose randomized for of clinically non-small HARMONi-X, PD-LX and Independent squamous head-to-head X%. positive Review XX% HARMONi-X double-blinded as sponsored Committee. expression versus for trial stratified TPS first-line a Moving pembrolizumab measured patients tumors with single pembrolizumab. and low of survival or a evaluating progression-free scores in In PD-LX a of or advanced study are the high or score score or input cancer monotherapy greater lung Phase in greater treatment X is
pembrolizumab. in survival This versus subgroup, significant have patients. PD-LX low, benefit setting patient demonstrated and other clinical a cancer progression-free high-risk across lung Notably, statistically trials high, non-squamous head-to-head other PD-LX squamous well cell non-small including in as as was Phase in improvement randomized histologies III no observed
when sub mentioned share information The and upcoming lung. our are histology conference lung for as within are previously, the more quarter. in clinical major analysis at of presented we set eager data in both next well subgroups HARMONi-X interim indication terms PD-LX by is steps as pathway informing this As development beyond groups an medical the to important
was clinical safety that breast We cancer Early rapidly touched collaboration glioblastoma. Anderson in across to the Center will already, with multiple X-year but would development be additional announced highlights identifying renal including the types expand colorectal benefit on partnership this skin research ivonescimab MD which the clinical month studies. them development had include will may ivonescimab, trials many cancer, of in potential last strategic MD program. most this and of of the tumor biomarkers evaluate our potential several lead quarter and Anderson to cancer, the like past carcinoma, accelerated activities. mention possibility Cancer has cell through to of and The ivonescimab's work solid
East our include Central Japan. territories, in licensed the our Europe, including America, all license to which addition America Middle include Caribbean, and Africa; territories and the Canada, Latin South countries the U.S., expanded America, Mexico We to original and in and
existing globe We as are around to expand we territories up ivonescimab our bring many as excited possible. the people as to to seek
I appointments In greater acknowledge to X moment that to our our strengthened with like new a would Board to team recently Directors. of take addition, we
genomicist, President VC technology role of leading cofounded can Huber, to cured. be with which In and patients and Mostafa inc. leading GRAIL Prior He Vice GRAIL, Board. Jeff to formerly well. our joined Vice and of to Mr. Technology seeking Dr. Capital, Alphabet executive being as a have Senior as a several in renowned helped the his companies Prior XXXX, as firm, CEO when mission-driven Chairman detect our founding Triatomic April odds a role technology, XXXX. and well has cancer has Google Inc., Officer to improve including known Jeff biomarker-driven Ronaghi diagnostics, development as played current joined was In cancer, company the GRAIL, transformational the as sequencing from executive XXXX June, Board next-generation Illumina's the early He for Chief he such it a at was platforms. Google
Calendar, Maps, during Over Google Jeff and of life as Google at XX he employees Gmail, Docs years Google over Google X Google Google, he and in at sciences his a Apps time X,XXX Google's X billion as cofounded as P&L effort Google Ads. of such led scaling and managed team development well Google.
is other also Jeff addition, a edge member several at In cutting companies. Board
have and unmet to perspectives make medical significant our and in with serious join Jeff's positive We they a the are to in mission difference need. patients fortunate Mostafa expertise as lives us of
ask financial to and a have our X.X and with a great ivonescimab. my member Finally, all express to I past of done to Manmeet members. heartfelt achieved take I Team team thanks that like across every to we position each now making moment details Summit, have and of our would Manmeet? team Bob a job is to like I as and work has honor outlook. with on our I one Summit, to described tremendous remarkable provide accomplishments a privilege years With This every will each of update, the the and team over Team would goals It thank reality. in
